AIRLINK 73.30 Decreased By ▼ -0.70 (-0.95%)
BOP 4.98 Decreased By ▼ -0.04 (-0.8%)
CNERGY 4.43 Increased By ▲ 0.01 (0.23%)
DFML 39.17 Decreased By ▼ -0.03 (-0.08%)
DGKC 85.38 Decreased By ▼ -0.71 (-0.82%)
FCCL 21.62 Decreased By ▼ -0.03 (-0.14%)
FFBL 34.00 Decreased By ▼ -0.01 (-0.03%)
FFL 9.78 Decreased By ▼ -0.14 (-1.41%)
GGL 10.60 Increased By ▲ 0.04 (0.38%)
HBL 113.25 Decreased By ▼ -0.64 (-0.56%)
HUBC 135.70 Decreased By ▼ -0.14 (-0.1%)
HUMNL 12.04 Increased By ▲ 0.14 (1.18%)
KEL 4.73 Decreased By ▼ -0.11 (-2.27%)
KOSM 4.48 Decreased By ▼ -0.05 (-1.1%)
MLCF 38.15 Decreased By ▼ -0.12 (-0.31%)
OGDC 135.50 Increased By ▲ 0.65 (0.48%)
PAEL 26.05 Decreased By ▼ -0.30 (-1.14%)
PIAA 19.24 Decreased By ▼ -1.56 (-7.5%)
PIBTL 6.73 Increased By ▲ 0.05 (0.75%)
PPL 122.30 Decreased By ▼ -0.70 (-0.57%)
PRL 27.15 Increased By ▲ 0.46 (1.72%)
PTC 14.19 Decreased By ▼ -0.14 (-0.98%)
SEARL 57.55 Decreased By ▼ -1.57 (-2.66%)
SNGP 67.40 Decreased By ▼ -2.10 (-3.02%)
SSGC 10.29 Decreased By ▼ -0.04 (-0.39%)
TELE 8.46 Decreased By ▼ -0.04 (-0.47%)
TPLP 11.13 Decreased By ▼ -0.10 (-0.89%)
TRG 63.84 Decreased By ▼ -1.01 (-1.56%)
UNITY 26.20 Decreased By ▼ -0.05 (-0.19%)
WTL 1.33 Decreased By ▼ -0.01 (-0.75%)
BR100 7,834 Decreased By -16.4 (-0.21%)
BR30 25,204 Decreased By -132.1 (-0.52%)
KSE100 75,143 Decreased By -63.9 (-0.08%)
KSE30 24,130 Decreased By -12.4 (-0.05%)

imagePARIS: Sanofi will hold a special board meeting on Wednesday at 0700 GMT to examine the French drugmaker's management structure, a source close to Sanofi told Reuters amid uncertainty over the future of its chief executive.

The board directors were hastily convened to the meeting on Tuesday evening, the source said. Representatives for Sanofi did not immediately reply to requests for comment outside of regular business hours.

Sanofi Chief Executive Chris Viehbacher had been unable to say on Tuesday whether he had the support of his board after the company's chairman declined to clarify his future during a meeting the previous day.

Several sources close to Sanofi's board told Reuters of an increasingly frosty relationship between Viehbacher and chairman Serge Weinberg, Sanofi's chairman since 2010.

Sanofi's first non-French boss, German-Canadian Viehbacher took his job in late 2008. He has transformed a very French drug company by making it much more international, winning the praise of many analysts and investors, but raising some hackles in Paris and directly butting heads with some board members over the past several months.

Les Echos newspaper this week published a letter from Viehbacher to the board, dated Sept. 4 and revealing his mistrust of Weinberg.

In the letter, Viehbacher said he had heard that Weinberg was "actively seeking a successor" to him. Viehbacher defended his track record - and urged the board to clarify his situation as soon as possible.

Sanofi's shares fell more than 10 percent on Tuesday, their biggest drop in 17 years, after the company warned its key diabetes business would probably not grow next year and as uncertainty over Viehbacher's role - which first surfaced on Monday - rattled investors.

Copyright Reuters, 2014

Comments

Comments are closed.